Suzhou Ribo Life Science Co (HKSE:06938) Total Operating Expense: HK$534.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06938 Suzhou Ribo Life Science Co Ltd HKSE:06938
9 GF Score
Price HK$54.15
! 2 Warning Signs
View Full Analysis

What is Suzhou Ribo Life Science Co Total Operating Expense?

Suzhou Ribo Life Science Co HKSE:06938 -4.07% 9 Total Operating Expense is HK$534.9 Mil as of Dec. 2025. GuruFocus rates HKSE:06938 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Suzhou Ribo Life Science Co's Total Operating Expense for the six months ended in Dec. 2025 was HK$243.0 Mil. Suzhou Ribo Life Science Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$534.9 Mil.

Suzhou Ribo Life Science Co Total Operating Expense Related Terms

Suzhou Ribo Life Science Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Suzhou Ribo Life Science Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Ribo Life Science Co Total Operating Expense Chart

Suzhou Ribo Life Science Co Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
406.55 381.22 426.36

Suzhou Ribo Life Science Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Operating Expense Get a 7-Day Free Trial 186.34 196.41 181.46 242.97 291.90
HKSE:06938
9GF Score
Suzhou Ribo Life Science Co Ltd HKSE:06938
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Ribo Life Science Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$534.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of HK$534.9 Mil mean?
Suzhou Ribo Life Science Co (HKSE:06938) has a Total Operating Expense of HK$534.9 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Suzhou Ribo Life Science Co and its competitors.
Is Suzhou Ribo Life Science Co's Total Operating Expense too high?
Suzhou Ribo Life Science Co's current Total Operating Expense is HK$534.9 Mil. Overall, Suzhou Ribo Life Science Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Ribo Life Science Co's Total Operating Expense compare to VRTX and REGN?
Suzhou Ribo Life Science Co's Total Operating Expense of HK$534.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Suzhou Ribo Life Science Co and its competitors. Suzhou Ribo Life Science Co's current Total Operating Expense is HK$534.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Ribo Life Science Co stock overvalued right now?
Suzhou Ribo Life Science Co (HKSE:06938) has a current Total Operating Expense of HK$534.9 Mil. The current Total Operating Expense is HK$534.9 Mil. Suzhou Ribo Life Science Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Suzhou Ribo Life Science Co (HKSE:06938), the current Total Operating Expense is HK$534.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Suzhou Ribo Life Science Co Business Description

Address No. 168 Yuanfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN, 215300
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.
9GF Score

Get the complete analysis for HKSE:06938

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$54.15
Price